Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 26;14(12):1186.
doi: 10.3390/brainsci14121186.

rTMS Modulation of Behavioral and Biological Measures in 3xTg-AD Mice

Affiliations

rTMS Modulation of Behavioral and Biological Measures in 3xTg-AD Mice

Eric P Kraybill et al. Brain Sci. .

Abstract

Background/objectives: The biological basis for behavioral manifestations of Alzheimer's disease remains unclear. Emotional and behavioral alterations of Alzheimer's disease can result in substantial caregiver burden and lack effective management. This study expands upon previous work investigating behavioral alterations in mice with Alzheimer's disease and a potential treatment of increasing brain-derived neurotrophic factor (BDNF) using repetitive transcranial magnetic stimulation (rTMS).

Methods: A total of 47 3xTg-AD (Alzheimer's) and 53 B6 (wildtype) mice were administered ANA12 (an antagonist of TrkB receptor) or Vehicle (saline) and then rTMS or Sham treatment daily. After 14 days of treatments and injections, mouse behavior was assessed under various behavioral cognitive tests. Mice were then perfused, and brain samples were processed for histology and protein assays. Brain homogenates were analyzed for BDNF and its downstream signaling molecules.

Results: Open field testing demonstrated that 3xTg-AD mice spent more time in the center than B6 mice. 3xTg-AD-Sham mice injected with ANA12 were the only group to travel significantly less distance than B6-ANA12-Sham or B6-Vehicle-Sham mice (p < 0.05), while 3xTg-AD-rTMS mice (irrespective of injection) were not significantly different from B6 mice. 3xTg-AD mice had significantly greater measured levels of BDNF and TrkB than the wild-type mice.

Conclusions: Treatment of Alzheimer's disease using rTMS positively affects elements of hypoactivity, but not all behavioral abnormalities. rTMS shifted 3xTg-AD open field behavioral test measures, generating significant differences between untreated 3xTg-AD and B6 genotypes. Despite its benefit, further investigation of rTMS as a treatment for Alzheimer's disease as well as its biological underpinnings are needed.

Keywords: ANA12; Alzheimer’s disease; disinhibition-like behavior; rTMS.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known financial interests or personal relationships that could have appeared to influence this work. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.

Figures

Figure 1
Figure 1
Representative stain of AD pathology in 3× mouse.
Figure 2
Figure 2
Lower exploratory activity in 3× mice was shown in the distance travelled in the Open Field Test (A), in the total object exploration in the familiarization phase of the Object Recognition Test (B) and in the total entries into arms in the Y Maze (C). Annotations in bars are the n in each group and the Tukey or genotype effect p values of significant results are shown.
Figure 3
Figure 3
Behavioral disinhibition phenotype was present in the 3× mice. In the center 3× spent more time (A) and had a slower velocity (B) than B6 mice; however, these differences were not present in the periphery (C) for the Open Field Test. Number of entries into the center zone between conditions (D). Represented trace images of activity from one 3× and one B6 mouse are shown (E). Annotations in bars are the n in each group and the Tukey p values of significant results are shown.
Figure 4
Figure 4
Genotype and ANA12 injections had differing effects on BDNF (A), TrkB (B) and downstream BDNF-TrkB pathway protein AKT (C). Example Western blot bands from TrkB and AKT (D). For full unaltered images of Westerns, see Supplementary Figure S1. Annotations in bars are the n in each group and the Tukey or genotype effect p values of significant results are shown.

Similar articles

Cited by

References

    1. Alzheimer’s Association Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2023;19:1598–1695. doi: 10.1002/alz.13016. - DOI - PubMed
    1. CDC About Alzheimer’s. Alzheimer’s Disease and Dementia. Published 15 August 2024. [(accessed on 22 November 2024)]; Available online: https://www.cdc.gov/alzheimers-dementia/about/alzheimers.html.
    1. Oxford A.E., Stewart E.S., Rohn T.T. Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy. Int. J. Alzheimer’s Dis. 2020;2020:5380346. doi: 10.1155/2020/5380346. - DOI - PMC - PubMed
    1. Kueper J.K., Speechley M., Montero-Odasso M. The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. J. Alzheimer’s Dis. 2018;63:423–444. doi: 10.3233/JAD-170991. - DOI - PMC - PubMed
    1. Craig D., Mirakhur A., Hart D.J., McIlroy S.P., Passmore A.P. A Cross-Sectional Study of Neuropsychiatric Symptoms in 435 Patients with Alzheimer’s Disease. Am. J. Geriatr. Psychiatry. 2005;13:460–468. doi: 10.1097/00019442-200506000-00004. - DOI - PubMed

LinkOut - more resources